ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

ASCO, ONS Issue Standards For Safe Chemotherapy Administration

October 2, 2009

CCOP Controversy Goes On: DCT Board Objects, Says It Was Left Out; Moorhead, DeVita Clarify Positions

February 19, 1982

NCI Grant Funding Payline To Begin At 16th Percentile In FY 2010

December 11, 2009

Sledge: Prepare for Genomic Information “Tsunami”

June 10, 2011

Groups Push for CMS Coverage for LDCT Lung Screening

October 3, 2014

Smokeless Tobacco Warning Bill May Go To House Floor

January 24, 1986